Antengene Corporation Limited (HK:6996) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Antengene Corporation Limited has announced that the Malaysian National Pharmaceutical Regulatory Agency approved a New Drug Application for XPOVIO® for two new indications in the treatment of multiple myeloma. This milestone reflects the company’s commitment to expanding its oncology portfolio and the potential for XPOVIO® to offer novel treatment options for patients. The company advises shareholders and potential investors to exercise caution when dealing in its shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.